Amalgamated Bank decreased its position in Illumina, Inc. (NASDAQ:ILMN) by 30.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 11,084 shares of the life sciences company’s stock after selling 4,758 shares during the period. Amalgamated Bank’s holdings in Illumina were worth $1,891,000 at the end of the most recent quarter.
A number of other hedge funds have also bought and sold shares of the company. Advocacy Wealth Management Services LLC acquired a new stake in Illumina during the first quarter worth about $102,000. Gemmer Asset Management LLC boosted its stake in Illumina by 5.7% in the first quarter. Gemmer Asset Management LLC now owns 686 shares of the life sciences company’s stock worth $117,000 after buying an additional 37 shares during the last quarter. Advisory Services Network LLC acquired a new stake in Illumina during the first quarter worth about $117,000. Bronfman E.L. Rothschild L.P. boosted its stake in Illumina by 3.6% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 1,198 shares of the life sciences company’s stock worth $204,000 after buying an additional 42 shares during the last quarter. Finally, Probity Advisors Inc. acquired a new stake in Illumina during the first quarter worth about $204,000. 96.85% of the stock is owned by institutional investors and hedge funds.
Illumina, Inc. (ILMN) traded up 0.01% during midday trading on Tuesday, hitting $176.61. The stock had a trading volume of 518,715 shares. Illumina, Inc. has a 52 week low of $119.37 and a 52 week high of $189.48. The company has a 50-day moving average price of $178.79 and a 200-day moving average price of $163.12. The stock has a market cap of $25.79 billion, a P/E ratio of 35.74 and a beta of 0.76.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Tuesday, April 25th. The life sciences company reported $0.64 earnings per share for the quarter, hitting the consensus estimate of $0.64. The company had revenue of $598 million during the quarter, compared to the consensus estimate of $590.51 million. Illumina had a return on equity of 21.21% and a net margin of 30.75%. The firm’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.71 EPS. Equities analysts expect that Illumina, Inc. will post $3.63 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Amalgamated Bank Reduces Stake in Illumina, Inc. (ILMN)” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://sportsperspectives.com/2017/06/20/amalgamated-bank-reduces-stake-in-illumina-inc-ilmn.html.
A number of analysts recently issued reports on the company. Vetr raised Illumina from a “buy” rating to a “strong-buy” rating and set a $196.75 target price for the company in a research note on Monday, April 24th. Zacks Investment Research cut Illumina from a “buy” rating to a “hold” rating in a research note on Thursday, April 13th. Evercore ISI raised Illumina from a “hold” rating to a “buy” rating and set a $190.00 target price for the company in a research note on Monday, February 27th. Leerink Swann raised Illumina from a “market perform” rating to an “outperform” rating and set a $195.00 target price for the company in a research note on Monday, March 20th. Finally, Deutsche Bank AG reaffirmed a “hold” rating and set a $175.00 price target (up from $165.00) on shares of Illumina in a research note on Saturday, April 29th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $165.02.
In related news, EVP Marc Stapley sold 2,000 shares of the stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $170.85, for a total transaction of $341,700.00. Following the sale, the executive vice president now owns 41,341 shares of the company’s stock, valued at approximately $7,063,109.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Charles Dadswell sold 145 shares of the stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $184.75, for a total value of $26,788.75. Following the sale, the senior vice president now directly owns 10,791 shares in the company, valued at approximately $1,993,637.25. The disclosure for this sale can be found here. Insiders have sold a total of 76,457 shares of company stock worth $13,761,498 in the last three months. 1.60% of the stock is currently owned by insiders.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.